Beijing Pins Medical starts a 10-patient trial of its hypoglossal implant for OSA
The device joins a field where Inspire Medical's version is already implanted, and a 2013 Apnex Medical trial of the same target was terminated.
Executive Summary
- Beijing Pins Medical Co., Ltd has registered a single-arm, open-label study of an implantable hypoglossal nerve stimulator for obstructive sleep apnea, a device-based alternative for patients who have failed or rejected CPAP.
- The device enters a field where several other hypoglossal nerve stimulation systems already carry Phase 3 or commercial-stage histories, including one from Inspire Medical Systems, so the trial's job is to reproduce known effects in a small cohort rather than establish a new mechanism.
- The sponsor's only prior trial of this device was terminated over a decade ago, even though its wider trial portfolio shows a clean completion record, a split that matters for reading how much confidence to place in the design this time.
- Because the trial has one arm, no comparator, and ten patients, its primary completion next year can establish tolerability and directional effect on apnea severity, not comparative superiority over CPAP or rival implants.
The trial
The study, listed as Not yet recruiting, plans to enroll 10 patients with moderate-to-severe obstructive sleep apnea, defined by an apnea-hypopnea index of 15 to 100 events per hour, who have already failed, been intolerant of, or been unwilling to continue positive airway pressure therapy. The primary endpoint is response based on the apnea-hypopnea index using a 3% oxygen desaturation criterion, measured three months after therapy activation. Secondary measures cover the Epworth Sleepiness Scale, the Functional Outcomes of Sleep Questionnaire, and device malfunction rates, also read at three months. The design is single-arm and open-label, with one treatment group and no masking. NCT07711678Implantable Hypoglossal Nerve Stimulation for Obstructive Sleep ApneaNCT07711678
A device category with history
Hypoglossal nerve stimulation for obstructive sleep apnea is not a new mechanism. At least eight other systems targeting the same nerve have run trials in this indication, including Inspire Medical Systems' Inspire System and a since-terminated Apnex Medical device. Beijing Pins Medical's own record with this device includes a completed Phase 2/3 study and a Phase 3 trial that was terminated in 2013. Across the target-indication pairing, 8 of 9 resolved trials completed rather than terminated, and the pairing has drawn 11 different sponsors since 2010.
Sponsor track record
Beijing Pins Medical Co., Ltd has run 26 trials across its portfolio, with 3 completed and none terminated in the sponsor-level count that excludes the Apnex-run 2013 study tied to this same device. Nineteen of its trials carry an unknown status in the registry, and three are currently recruiting. The gap between a clean sponsor-level completion record and the one prior terminated trial specific to this device is the detail that matters most for judging how the new study is executed.
What the design can and cannot show
With ten patients, one arm, and no blinding, the trial can establish whether the device is tolerated and whether apnea severity moves in the expected direction by three months post-activation. It cannot establish comparative effectiveness against CPAP, against Inspire Medical's approved system, or against other hypoglossal stimulators already in the field, none of which appear as a comparator arm in this design. NCT07711678Implantable Hypoglossal Nerve Stimulation for Obstructive Sleep ApneaNCT07711678
This analysis was produced using AI-assisted reporting systems, AppliedXL data, and official public records. These systems undergo editorial review, quality checks, and regular audits by human experts. Errors may still occur, as with any automated system. Always consult the linked primary sources. Read our AI Editorial Policy.